Oct 11, 2014 at 14:53 | Source:
Analysts at Motilal Oswal believe that Lupin, Ranbaxy, Cadila Healthcare, GSK Pharma, Torrent Pharma and Alembic Pharma will report stronger overall operational performance during this quarter.
Sep 12, 2014 at 13:42 | Source:
Taro has recalled two lots of a key drug on September 2, citing failed content uniformity specifications, according to drug regulator. The drug contributes nearly 5 percent of Taro's sales, analysts say.
Sep 10, 2014 at 09:45 | Source: CNBC
The yen`s near-term outlook hinges on the direction of the US dollar, say analysts, who expect further downside in the Japanese currency.
Aug 13, 2014 at 15:33 | Source: CNBC-TV18
According to Uday Baldota, people should not focus too much on one-time sales of the company as Sun Pharma is confident of achieving its full year guidance.
Aug 11, 2014 at 17:40 | Source: CNBC-TV18
Revenue is seen going up by 17.5 percent to Rs 4,115 crore during the quarter from Rs 3,503 crore in the year-ago period driven by US sales.
Jun 30, 2014 at 13:38 | Source:
Credit Suisse believes if price increase sustains, sales and EBITDA for Taro could increase by USD 300 million (or 70 percent increase from FY14 EBITDA) and have factored in only half of the price increase and wait for competition to react.
Jun 30, 2014 at 13:00 | Source:
Sun Pharma continues its rally after Taro rallied 17 percent in the US markets on Friday. Sun owns a 70 percent stake in Taro and the Israel-based subsidiary contributes 28 percent to Sun's profits. Credit Suisse believes recent price increase has potential to add USD 300 mn to Taro's sales.
Jun 27, 2014 at 11:15 | Source:
Ranbaxys subsidiary Ohm Lab has received drug regulator US Food and Drug Administration's nod for generic version of Novartis blood pressure drug Diovan.
May 30, 2014 at 16:14 | Source: CNBC-TV18
Uday Baldota says Taros performance has been accounted for in the sales growth guidance.
Apr 09, 2014 at 12:49 | Source:
So far, the only effective setback received by Sun Pharma is its plan to acquire a 100 percent stake in Taro, in 2010, which did not succeed.
Messages on Taro »


Platinum Member


Ranbaxy Labs  

One must understand that SUN cannot b redflagged bcs its main subsidiary is TARO is situated in Iserael which has more strintest practoces more than even USA.Also USA realised that by redflagging Indian cos like RBaxy it is USA public which is suffering bcs of nongen drugs produced by another

6.26 PM Jul 7th


Platinum Member


Suven Life Scie  

That`s also a good strategy.Something I hear/read,even RJ follows.SLS management is conservative & Mr. Jasti has always been very candid about his company.Recently,they had achieved aprroval for Malathion,to be marketed by Taro.The bottomline will be 2MUSD every year from this product alone! See

9.23 PM Jul 3rd


Silver Member


Sun Pharma  

Ultimately patience is paying rich dividends. Good to know Taro has shot up by more than 16%. Sun should open with a big gap monday morning. Cheers!

8.49 PM Jun 28th


Gold Member


Sun Pharma  

Awsome Taro....16% up at 137 !! good news coming for sun pharma as well !!

6.53 PM Jun 28th


Gold Member


Sun Pharma  

dear kurken...its other way buddy they will acquire mnc`s like taro,caraco,dusa etc...list not going to stop and its a professionally managed company...stay invested...

10.27 AM May 30th


New Member



Guys: Hope you got benefitted by my buy call on Lupin today... all the pharma stocks buzzing Dr. Reddy, Lupin, Div lab... tomorrow sun pharma likely to post good results.. so continue buy Lupin as near term target is 960. Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro

4.06 PM May 28th


New Member


Sun Pharmaceutical Industries  

Strong results of Taro is set to boost Sun Pharma`s Q4FY2014 results. Taro Pharma contributes near 48% of US revenue and 29% of total revenue. Sharekhan expect Sun Pharma to report a revenue of Rs4290 crore (39.7% YoY)and net profit of Rs1313 crore (29.8% YoY) in Q4FY2014. Sharekhan can expect

4.03 PM May 28th

Sun Pharma  

Taro EPS up 44% for FY.

2.43 PM May 28th

Sun Pharma  

Net income attributable to Taro was $360.4 million compared to $266.2 million, a $94.2 million increase, resulting in diluted earnings per share of $8.14 compared to $5.95 Net sales of $759.3 million, increased $88.3 million, or 13.2%, with a slight decrease in volumes Taro`s FY 14 results. EPS

2.42 PM May 28th


New Member


Sun Pharma  

Taro posted spectacular results this time around. Sun Pharma will also post good results tomorrow. Exporters are doing good currently, so it is a good idea to buy sun pharma today, a combination of good results and short covering on expiry can easily take this stock to 600 levels. 580 can be used

1.54 PM May 28th

News across the web »
Oct 22, 2014 at 23:36 | Source: BBC
Sep 18, 2014 at 04:37 | Source: Calcutta Telegraph News
Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.